About this episode

Ken Song discusses the development of bispecific T-cell engaging antibodies for autoimmune diseases.

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

More episodes of The Long Run with Luke Timmerman

• Ep200: Richard Pops Reflects on a 35-Year Career in Biotech · May 5, 2026 · 1h 14m
• Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery · April 7, 2026 · 1h 17m
• Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature · March 31, 2026 · 1h 17m
• Ep196: Otello Stampacchia on Europe's Biotech Crisis · March 17, 2026 · 1h 3m
• Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery · February 17, 2026 · 1h 9m
• Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines · January 22, 2026 · 1h 5m

Explore listener stats, chart rankings, contacts and more on the The Long Run with Luke Timmerman podcast page.